search
Back to results

HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections (HYPER-Seg)

Primary Purpose

Lung Neoplasm, Pulmonary Metastasis

Status
Not yet recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Hyperspectral Imaging
Sponsored by
LungenClinic Grosshansdorf
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Lung Neoplasm focused on measuring Hyperspectral Imaging, Lung cancer, Segmentectomy, Indocyanine green, Intersegmental plane, Machine learning strategies

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Histologically confirmed lung cancer stage I/II or malignancy suspicious nodules Segmentectomy is oncologically indicated or impaired pulmonary and/or cardiac function prevent anatomical resection Male or female patients aged ≥ 18 years without upper age limit Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance (CrCl ≥ 50 mL/min, Cockcroft-Gault formula) Total bilirubin ≤ 1.5 x upper limit of normal (except patients with Gilbert Syndrome (Morbus Meulengracht) in whom total bilirubin < 3.0 mg/dL is allowed) Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase)/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase) ≤ 2.5 x upper limit of normal Full legal capacity Written informed consent obtained according to international guidelines and local laws Ability to understand the nature of the trial and the trial related procedures and to comply with them Exclusion Criteria: Requirement of a lobectomy or pneumonectomy to achieve complete resection Allergy to indocyanine green or iodine Hyperthyroidism Current or planned pregnancy, nursing period (if defined as requirement of clinical routine treatment) Medical condition which poses a high risk to undergo surgery as defined by the investigator Covid19 / SARS-CoV2-infection at time of screening Participation in any other interventional clinical trial within the last 30 days before the start of this trial Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed Known or persistent abuse of medication, drugs or alcohol Person who is in a relationship of dependence/employment with the coordinating investigator or the investigator

Sites / Locations

  • LungenClinic Großhansdorf

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intersegmental plane identification by HSI and ICG

Arm Description

Hyperspectral Imaging Intersegmental plane identification: Defined as distance between intersegmental plane identification with Hyperspectral Imaging compared to near-infrared indocyanine green fluorescence.

Outcomes

Primary Outcome Measures

Intersegmental Plane identification
Distance between intersegmental plane identification with Hyperspectral Imaging compared to near-infrared indocyanine green fluorescence

Secondary Outcome Measures

Tumor distance [mm]
Shortest distance between tumor and HSI and ICG-fluorescence predicted intersegmental plane
7-item binary rating scale for feasibilty of HSI measurement
Evaluation of feasibility of HSI and ICG-fluorescence intersegmental plane identification using a 7-item binary rating scale

Full Information

First Posted
November 26, 2022
Last Updated
January 6, 2023
Sponsor
LungenClinic Grosshansdorf
Collaborators
Institute of Medical Technology and Intelligent Systems, Hamburg University of Technology, Germany
search

1. Study Identification

Unique Protocol Identification Number
NCT05676788
Brief Title
HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections
Acronym
HYPER-Seg
Official Title
Hyperspectral Imaging for Intersegmental Plane Identification During Sublobar Pulmonary Resections in Lung Cancer Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
April 2023 (Anticipated)
Primary Completion Date
May 2026 (Anticipated)
Study Completion Date
June 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LungenClinic Grosshansdorf
Collaborators
Institute of Medical Technology and Intelligent Systems, Hamburg University of Technology, Germany

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is the identification of the intersegmental plane and navigation during sublobar pulmonary resections in lung cancer using Hyperspectral Imaging, the comparison with ICG fluorescence intersegmental plane identification, and the establishment of automatic intersegmental plane navigation using machine learning strategies for intraoperative navigation.
Detailed Description
Lung cancer is the leading cause of cancer-related death worldwide. Due to the generalization of screening strategies, especially for risk populations, an increasing number of lung cancer cases are detected in an early stage. In this regard, lung cancer is also increasingly diagnosed in patients with impaired pulmonary function. For preserving lung function and reducing complication incidence, pulmonary segmentectomies are currently evaluated in this cohort. Thus, the latest version of the German guideline for the prevention, diagnosis, treatment and follow-up of lung cancer recommends segmentectomy for patients with impaired pulmonary function in tumor stage I/II. However, the identification of the intersegmental plane - the key step of segmentectomy - remains challenging. Inaccurate recognition of the intersegmental plane may lead to dysfunction of the remaining lung tissue, mismatching of ventilation or blood flow, or long-term air leakage after surgery, which even requires unplanned secondary surgery. Indocyanine green (ICG) is one the latest evaluated identification methods and is considered as gold standard. Hyperspectral Imaging (HSI) - a newly established intraoperative imaging technique - enables a non-invasive evaluation of tissue perfusion and the discrimination of pulmonary tissue with different tissue perfusion during segmentectomies. The purpose of this prospective, single-center, non-inferiority IDEAL Stage 2b study is the identification of the intersegmental plane and navigation during sublobar pulmonary resections in lung cancer using Hyperspectral Imaging, the comparison with ICG fluorescence intersegmental plane identification, and the establishment of automatic intersegmental plane navigation using machine learning strategies for intraoperative navigation. To address this, the intersegmental plane will be detected by both HSI and ICG-fluorescence during pulmonary segmentectomies and the correspondence of the two identification methods will be compared with one another. Using machine learning strategies, the detection of perfused and non-perfused pulmonary tissue and intersegmental plane will be analyzed. Finally, the investigators will study motion tracking for the improvement of future HSI illustrations during surgery. The hypothesis of this study is that HSI could improve the intraoperative navigation during pulmonary segmentectomies providing as reliable intersegmental plane identification as the gold standard of indocyanine green fluorescence. In this case, an intravenous application of fluorescent dye would not be required anymore for the intersegmental plane identification. In the case of complex segment resection, a large amount or repeated use of ICG is necessary due to its short pulmonary circulation time. Multiple use of ICG may result in ICG entering the target lung tissue through the bronchial circulation and increases the risk of adverse drug reactions of ICG. In contrast, the advantages of HSI would be a faster and repetitive measurement during surgery. There will be a potential for reducing the total measurement time during intersegmental plane dissection (10 seconds vs. 3 minutes / measurement) and consequently patient's burden. In this context, several studies of HSI-based perfusion measurement during esophageal or colorectal surgery showed already an improved patients' outcome. Furthermore, HSI can be used for surgery on patients with hyperthyroidism or impaired renal or hepatic function. In order to support this hypothesis, a prospective non-inferiority trial design will be used in this study. To ensure the quality of data acquisition and reporting, the study will be conducted in accordance with the IDEAL reporting guidelines. During pulmonary segmentectomies, the intersegmental plane will be identified by both HSI and ICG fluorescence. The determined HSI intersegmental margin will be benchmarked against the ground truth ICG fluorescence and the feasibility and reproducibility of HSI and ICG mapping will be studied. Machine learning methods have greatly improved the interpretation of subtle patterns in medical image data. Convolutional neural networks (CNNs) can be considered state-of-the-art for classification and segmentation of medical images. The investigators will extend CNN-based methods for HSI classification and particularly study patch-based differentiation between perfused and non-perfused tissue using ICG and HSI data acquired at the same position. A further challenge is the relatively slow acquisition of HSI (10 seconds/measurement), which makes it prone to motion artifacts, e.g., due to pulsatile motion. To address this, the investigators will study motion tracking, which is also relevant for the future illustration of the segment boundary during surgery. Machine learning approaches and particularly CNNs allow to directly optimize classifiers based on actual clinical data and the spectral dimension can be handled in a straightforward fashion. Moreover, as a versatile method for image processing, CNNs can also be used for localization and motion compensation during intraoperative imaging, e.g., they can be trained to detect image features and their motion in red/green/blue image streams. This is interesting for the proposed HSI data acquisition, which is based on a sequence of measurements which are sensitive to tissue motion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Neoplasm, Pulmonary Metastasis
Keywords
Hyperspectral Imaging, Lung cancer, Segmentectomy, Indocyanine green, Intersegmental plane, Machine learning strategies

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intersegmental plane identification by HSI and ICG
Arm Type
Experimental
Arm Description
Hyperspectral Imaging Intersegmental plane identification: Defined as distance between intersegmental plane identification with Hyperspectral Imaging compared to near-infrared indocyanine green fluorescence.
Intervention Type
Device
Intervention Name(s)
Hyperspectral Imaging
Intervention Description
Identification of the intersegmental plane
Primary Outcome Measure Information:
Title
Intersegmental Plane identification
Description
Distance between intersegmental plane identification with Hyperspectral Imaging compared to near-infrared indocyanine green fluorescence
Time Frame
directly before pulmonary intersegmental plane dissection
Secondary Outcome Measure Information:
Title
Tumor distance [mm]
Description
Shortest distance between tumor and HSI and ICG-fluorescence predicted intersegmental plane
Time Frame
immediately after surgery
Title
7-item binary rating scale for feasibilty of HSI measurement
Description
Evaluation of feasibility of HSI and ICG-fluorescence intersegmental plane identification using a 7-item binary rating scale
Time Frame
immediately after surgery
Other Pre-specified Outcome Measures:
Title
Machine Learning
Description
Intersegmental plane identification with machine learning strategies. To predicted intersegmental plane by the machine learning algorithm developed in this project. The machine learning algorithm is trained on thoracoscopic HSI image and specimen data to predict if the intersegmental plane is displayed correctly during surgery.
Time Frame
one week after surgery
Title
Safety of HSI
Description
Safety will be evaluated by measuring the rates of adverse reactions to HSI and ICG dye, intraoperative complications, and perioperative complications using the Ottawa Thoracic Morbidity and Mortality Classification
Time Frame
at 10 days and 6 weeks after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed lung cancer stage I/II or malignancy suspicious nodules Segmentectomy is oncologically indicated or impaired pulmonary and/or cardiac function prevent anatomical resection Male or female patients aged ≥ 18 years without upper age limit Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance (CrCl ≥ 50 mL/min, Cockcroft-Gault formula) Total bilirubin ≤ 1.5 x upper limit of normal (except patients with Gilbert Syndrome (Morbus Meulengracht) in whom total bilirubin < 3.0 mg/dL is allowed) Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase)/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase) ≤ 2.5 x upper limit of normal Full legal capacity Written informed consent obtained according to international guidelines and local laws Ability to understand the nature of the trial and the trial related procedures and to comply with them Exclusion Criteria: Requirement of a lobectomy or pneumonectomy to achieve complete resection Allergy to indocyanine green or iodine Hyperthyroidism Current or planned pregnancy, nursing period (if defined as requirement of clinical routine treatment) Medical condition which poses a high risk to undergo surgery as defined by the investigator Covid19 / SARS-CoV2-infection at time of screening Participation in any other interventional clinical trial within the last 30 days before the start of this trial Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed Known or persistent abuse of medication, drugs or alcohol Person who is in a relationship of dependence/employment with the coordinating investigator or the investigator
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
David B Ellebrecht, MD
Phone
+4941026012201
Email
d.ellebrecht@lungenclinic.de
Facility Information:
Facility Name
LungenClinic Großhansdorf
City
Großhansdorf
ZIP/Postal Code
22927
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections

We'll reach out to this number within 24 hrs